
Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat. After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/4iBzJU0 For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
最近 90 天内有 1 个信号。
该公司进入各个市场的顺序 — 从最早到最新
Director
注册以查看完整信号动态
Exelixis 的国际扩张与竞争对手的对比情况
条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
Exelixis你 | 1 | 1 | -100% | 1 | 31 |
Associate GPO Strategic Partner Marketing and Operations Director
查看职位Alameda, CA · 上周
Associate Director, Stability Management
查看职位Alameda, CA · 2周前
PSC Operations Management Director
查看职位Alameda, CA · 2周前
没有进行中的营销活动
注册以跟踪该公司,并在发生变化时第一时间获得提醒。
ADG126与抗PD-1联合治疗MSS结直肠癌显示良好效果。更高剂量和频率展现临床效益,计划在2024年扩大试验。
Exelixis将在分析师降级后发布第三季度业绩。生物科技公司必须在上一季度数据喜忧参半后交出亮眼成绩。
FirstBio Therapeutics成立科学咨询委员会,由全球制药研发领导者组成,推进FB849免疫疗法和神经退化性疾病管线开发。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Exelixis 的业务、市场和增长信号的快速解答。
